(a) Schedule I shall consist of the drugs and other
substances, by whatever official name, common or usual name,
chemical name, or brand name designated, listed in this section.

(b) Opiates. Unless specifically excepted or unless listed in
another schedule, any of the following opiates, including their
isomers, esters, ethers, salts and salts of isomers, esters and
ethers, whenever the existence of such isomers, esters, ethers and
salts is possible within the specific chemical designation (for
purposes of subdivision (34) of this subsection only, the term
isomer includes the optical and geometric isomers):

(c) Opium derivatives. -- Unless specifically excepted or
unless listed in another schedule, any of the following opium
immediate derivatives, its salts, isomers and salts of isomers
whenever the existence of such salts, isomers and salts of isomers
is possible within the specific chemical designation:

(1) Acetorphine;

(2) Acetyldihydrocodeine;

(3) Benzylmorphine;

(4) Codeine methylbromide;

(5) Codeine-N-Oxide;

(6) Cyprenorphine;

(7) Desomorphine;

(8) Dihydromorphine;

(9) Drotebanol;

(10) Etorphine (except HCl Salt);

(11) Heroin;

(12) Hydromorphinol;

(13) Methyldesorphine;

(14) Methyldihydromorphine;

(15) Morphine methylbromide;

(16) Morphine methylsulfonate;

(17) Morphine-N-Oxide;

(18) Myrophine;

(19) Nicocodeine;

(20) Nicomorphine;

(21) Normorphine;

(22) Pholcodine;

(23) Thebacon.

(d) Hallucinogenic substances. -- Unless specifically excepted
or unless listed in another schedule, any material, compound,
mixture or preparation, which contains any quantity of the
following hallucinogenic substances, or which contains any of its
salts, isomers and salts of isomers, whenever the existence of such
salts, isomers, and salts of isomers is possible within the
specific chemical designation (for purposes of this subsection
only, the term "isomer" includes the optical, position and
geometric isomers):

(26) Peyote; meaning all parts of the plant presently
classified botanically as Lophophora williamsii Lemaire, whether
growing or not, the seeds thereof, any extract from any part of
such plant, and every compound, manufacture, salts, immediate
derivative, mixture or preparation of such plant, its seeds or extracts;

(27) N-ethyl-3-piperidyl benzilate;

(28) N-methyl-3-piperidyl benzilate;

(29) Psilocybin;

(30) Psilocyn;

(31) Tetrahydrocannabinols; synthetic equivalents of the
substances contained in the plant, or in the resinous extractives
of Cannabis, sp. and/or synthetic substances, immediate derivatives
and their isomers with similar chemical structure and
pharmacological activity such as the following:

delta-1 Cis or trans tetrahydrocannabinol, and their optical
isomers;

delta-6 Cis or trans tetrahydrocannabinol, and their optical
isomers;

delta-3,4 Cis or trans tetrahydrocannabinol, and its optical
isomers;

(Since nomenclature of these substances is not internationally
standardized, compounds of these structures, regardless of
numerical designation of atomic positions covered.)

(53)Synthetic cannabinoids or any material, compound, mixture
or preparation which contains any quantity of the following
substances, including their analogues, congeners, homologues,
isomers, salts and salts of analogues, congeners, homologues and
isomers, as follows:

(54) Synthetic cannabinoids including any material, compound,
mixture or preparation that is not listed as a controlled substance
in Schedule I through V, is not a federal Food and Drug
Administration approved drug or used within legitimate and approved
medical research and which contains any quantity of the following
substances, their salts, isomers, whether optical positional or
geometric, analogues, homologues and salts of isomers, analogues
and homologues, unless specifically exempted, whenever the
existence of these salts, isomers, analogues, homologues and salts
of isomers, analogues and homologues if possible within the
specific chemical designation:

(A) Tetrahydrocannabinols meaning tetrahydrocannabinols which
are naturally contained in a plant of the genus cannabis as well as
synthetic equivalents of the substances contained in the plant or
in the resinous extractives of cannabis or synthetic substances, derivatives and their isomers with analogous chemical structure and
or pharmacological activity such as the following:

(i) DELTA-1 CIS OR trans tetrahydrocannabinol and their
Optical isomers.

(ii) DELTA-6 CIS OR trans tetrahydrocannabinol and their
optical isomers.

(iii) DELTA-3,4 CIS or their trans tetrahydrocannabinol and
their optical isomers.

(B) Naphthoylindoles or any compound containing a 3-(-1-
Napthoyl) indole structure with substitution at the nitrogen atom
of the indole ring whether or not further substituted in the indole
ring to any extent and whether or not substituted in the naphthyl
ring to any extent. This shall include the following:

(i) JWH 015;

(ii) JWH 018;

(iii) JWH 019;

(iv) JWH 073;

(v) JWH 081;

(vi) JWH 122;

(vii) JWH 200;

(viii) JWH 210;

(ix) JWH 398;

(x) AM 2201;

(xi) WIN 55,212.

(55) Naphylmethylindoles or any compound containing a
1hindol-3-yl-(1-naphthyl) methane structure with a substition at
the nitrogen atom of the indole ring whether or not further
substituted in the indole ring to any extent and whether or not
substituted in the naphthyl ring to any extent. This shall include,
but not be limited to, JWH 175 and JWH 184.

(56) Naphthoylpyrroles or any compound containing a 3-(1-
Naphthoyl) pyrrole structure with substitution at the nitrogen atom
of the pyrrole ring whether or not further substituted in the
pyrrole ring to any extent and whether or not substituted in the
naphthyl ring to any extent. This shall include, but not be
limited to, JWH 147 and JWH 307.

(57) Naphthylmethylindenes or any compound containing a
Naphthylideneindene structure with substitution at the 3- Position
of the indene ring whether or not further substituted in the indene
ring to any extent and whether or not substituted in the naphthyl
ring to any extent. This shall include, but not be limited to, JWH
176.

(58) Phenylacetylindoles or any compound containing a 3-
Phenylacetylindole structure with substitution at the nitrogen atom
of the indole ring whether or not further substituted in the indole
ring to any extent and whether or not substituted in the phenyl
ring to any extent. This shall include the following:

(A) RCS-8, SR-18 OR BTM-8;

(B) JWH 250;

(C) JWH 203;

(D) JWH 251;

(E) JWH 302.

(59) Cyclohexylphenols or any compound containing a 2-(3-
hydroxycyclohexyl) phenol structure with a substitution at the
5-position of the phenolic ring whether or not substituted in the
cyclohexyl ring to any extent. This shall include the following:

(A) CP 47,497 and its homologues and analogs;

(B) Cannabicyclohexanol;

(C) CP 55,940.

(60) Benzoylindoles or any compound containing a 3-(benzoyl)
indole structure with substitution at the nitrogren atom of the
indole ring whether or not further substituted in the indole ring
to any extent and whether or not substituted in the phenyl ring to
any extent. This shall include the following:

(62) Dibenzopyrans or any compound containing a 11-hydroxydelta 8-tetrahydrocannabinol structure with substitution
on the 3-pentyl group. This shall include HU-210, HU-211, JWH 051
and JWH 133.

(63) Adamantoylindoles or any compound containing a 3-(-1-
Adamantoyl) indole structure with substitution at the nitrogen atom
of the indole ring whether or not further substituted in the
adamantoyl ring system to any extent. This shall include AM1248.

(64) Tetramethylcyclopropylindoles or any compound containing
A 3-tetramethylcyclopropylindole structure with substitution at the
nitrogen atom of the indole ring whether or not further substituted
in the indole ring to any extent and whether or not substituted in
the tetramethylcyclopropyl ring to any extent. This shall include
UR-144 and XLR-11.

(65) N-(1-Adamantyl)-1-pentyl-1h-indazole-3-carboxamide. This
shall include AKB48.

(66) Any other synthetic chemical compound that is a
Cannabinoid receptor type 1 agonist as demonstrated by binding
studies and functional assays that is not listed in Schedules II,
III, IV and V, not federal Food and Drug Administration approved
drug or used within legitimate, approved medical research. Since
nomenclature of these substances is not internationally
standardized, any immediate precursor or immediate derivative of
these substances shall be covered.

(e) Depressants. -- Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following substances
having a depressant effect on the central nervous system, including
its salts, isomers and salts of isomers whenever the existence of
such salts, isomers and salts of isomers is possible within the
specific chemical designation:

(1) Mecloqualone;

(2) Methaqualone.

(f) Stimulants. -- Unless specifically excepted or unless
listed in another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following substances
having a stimulant effect on the central nervous system, including
its salts, isomers and salts of isomers:

(1) Aminorex; some other names: aminoxaphen; 2-amino-5-
phenyl-2-oxazoline; or 4,5-dihydro-5-phenyl-2-oxazolamine;

(2) Cathinone; some trade or other names: 2-amino-1-phenyl-1-
propanone, alpha-aminopropiophenone, 2-aminopropiophenone and
norephedrone;

(2)N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide
(thenylfentanyl), its optical isomers, salts and salts of isomers.

(3) N-benzylpiperazine, also known as BZP.

(h) The following controlled substances are included in
Schedule I:

(1) Synthetic Cathinones or any compound, except bupropion or
compounds listed under a different schedule, or compounds used
within legitimate and approved medical research, structurally derived from 2- Aminopropan-1-one by substitution at the 1-position
with Monocyclic or fused polycyclic ring systems, whether or not
the compound is further modified in any of the following ways:

(A) By substitution in the ring system to any extent with
Alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl or halide
Substituents whether or not further substituted in the ring system
by one or more other univalent substituents.

(B) By substitution at the 3-position with an acyclic alkyl
substituent.

(C) By substitution at the 2-amino nitrogen atom with alkyl,
dialkyl, benzyl or methoxybenzyl groups.

(D) By inclusion of the 2-amino nitrogen atom in a cyclic
structure.

(2) Any other synthetic chemical compound that is a
Cannabinoid receptor type 1 agonist as demonstrated by binding
studies and functional assays that is not listed in Schedules II,
III, IV and V, not federal Food and Drug Administration approved
drug or used within legitimate, approved medical research.
Note: WV Code updated with legislation passed through the 2014 1st Special Session
The WV Code Online is an unofficial copy of the annotated WV Code, provided as a convenience. It has NOT been edited for publication, and is not in any way official or authoritative.